HUMAN INTERLEUKIN 2 IN IMMUNODEFICIENCY SYNDROMES

Important note: Information in this article was accurate in 1987. The state of the art may have changed since the publication date.

HUMAN INTERLEUKIN 2 IN IMMUNODEFICIENCY SYNDROMES

Serono Symp Publ Raven Press; 19:201-14 1985. Unique Identifier : AIDSLINE ICDB/87628344
Welte K; Merrtelsmann R; Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York,; NY 10021

Abstract: The subject of human interleukin-2 (IL-2) in immunodeficiency syndromes is first reviewed, under the following headings: IL-2 production and response in acquired immunodeficiency syndrome (AIDS), hemophilia with AIDS, combined varied immunodeficiency, patients (pts) after bone marrow transplantation, and congenital immune defects. Next, in vivo effects of IL-2 are considered under the following headings: general considerations, murine studies, and Phase I clinical trial (preliminary results). In vitro tests have documented IL-2 production defects and partial or complete restoration of defective T cell proliferative response to exogenous IL-2 in many pts. Since many pts did not show complete restoration of T cell proliferation, even upon addition of higher concentrations of exogenous IL-2, not only defective IL-2 production but also defective IL-2 responsiveness appears to play a role in the immune deficit in these pt groups. Initial in vivo studies in both mice and humans have documented biological activity and minimal to no side-effects at the dosages employed up to now. Whether IL-2 will be efficacious in an in vivo setting of congenital or acquired immunodeficiency or in autologous, spontaneously arising tumor models remains to be determined. (74 Refs)

Keywords: Acquired Immunodeficiency Syndrome/IMMUNOLOGY Bone Marrow/TRANSPLANTATION Bone Marrow Transplantation Cytotoxicity, Immunologic/DRUG EFFECTS Drug Evaluation Hemophilia/IMMUNOLOGY Human Immunity, Cellular/DRUG EFFECTS Immunologic Deficiency Syndromes/*IMMUNOLOGY/THERAPY Interleukin-2/*PHYSIOLOGY/THERAPEUTIC USE Leukemia, Lymphocytic/IMMUNOLOGY Lymphocyte Transformation/DRUG EFFECTS T-Lymphocytes/IMMUNOLOGY MEETING PAPER

870330
M8730287

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1987. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1987. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .